Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Adenocarcinoma of the Esophagogastric Junction | Research

Evaluating prognostic value and stage migration effects using a positive lymph node ratio in adenocarcinoma of the esophagogastric junction

Authors: Hajime Kamiya, Shuhei Komatsu, Keiji Nishibeppu, Takuma Ohashi, Hirotaka Konishi, Atsushi Shiozaki, Takeshi Kubota, Hitoshi Fujiwara, Kazuma Okamoto, Eigo Otsuji

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Adenocarcinoma of the esophagogastric junction (AEG) is increasing worldwide. Lymph node metastasis is an important clinical issue in AEG patients. This study investigated the usefulness of a positive lymph node ratio (PLNR) to stratify prognosis and evaluate stage migration.

Methods

We retrospectively analysed 117 consecutive AEG patients (Siewert type I or II) who received a lymphadenectomy between 2000 and 2016.

Results

A PLNR cut-off value of 0.1 most effectively stratified patient prognosis into two groups (P < 0.001). Also, prognosis could be clearly stratified into four groups: PLNR = 0, 0 < PLNR < 0.1, 0.1  PLNR < 0.2, and 0.2  PLNR (P < 0.001, 5-year survival rates (88.6%, 61.1%, 34.3%, 10.7%)). A PLNR  0.1 significantly correlated with tumour diameter  4 cm (P < 0.001), tumour depth (P < 0.001), greater pathological N-status (P < 0.001), greater pathological Stage (P < 0.001), and oesophageal invasion length  2 cm (P = 0.002). A PLNR  0.1 was a poor independent prognostic factor (hazard ratio 6.47, P < 0.001). The PLNR could stratify prognosis if at least 11 lymph nodes were retrieved. A 0.2 PLNR cut-off value discriminated a stage migration effect in pN3 and pStage IV (P = 0.041, P = 0.015) patients; PLNR  0.2 might potentially diagnose a worse prognosis and need meticulous follow-up post-surgery.

Conclusion

Using PLNR, we can evaluate the prognosis and detect higher malignant cases who need meticulous treatments and follow-up in the same pStage.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer 2021. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer 2021.
2.
go back to reference Komatsu S, Otsuji E. Essential updates 2017/2018: recent topics in the treatment and research of gastric cancer in Japan. Ann Gastroenterol Surg. 2019;3(6):581–91.CrossRefPubMedPubMedCentral Komatsu S, Otsuji E. Essential updates 2017/2018: recent topics in the treatment and research of gastric cancer in Japan. Ann Gastroenterol Surg. 2019;3(6):581–91.CrossRefPubMedPubMedCentral
3.
go back to reference de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.CrossRefPubMed de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.CrossRefPubMed
4.
go back to reference Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. Association between Helicobacter pylori Eradication and Gastric Cancer incidence: a systematic review and Meta-analysis. Gastroenterology. 2016;150(5):1113–1124e1115.CrossRefPubMed Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. Association between Helicobacter pylori Eradication and Gastric Cancer incidence: a systematic review and Meta-analysis. Gastroenterology. 2016;150(5):1113–1124e1115.CrossRefPubMed
5.
go back to reference Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, Shimoda T. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23(11):1662–5.CrossRefPubMed Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, Shimoda T. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23(11):1662–5.CrossRefPubMed
6.
go back to reference Siewert JR. CARCINOMA OF THE CARDIA: Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection. Dis Esophagus. 1996;9:173–82. Siewert JR. CARCINOMA OF THE CARDIA: Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection. Dis Esophagus. 1996;9:173–82.
7.
go back to reference Brierley JDGMWC, et al. editors. TNM Classification of Malignant Tumours, 8th edn. Wiley Blackwell: Union for International Cancer Control (UICC) 2017. Brierley JDGMWC, et al. editors. TNM Classification of Malignant Tumours, 8th edn. Wiley Blackwell: Union for International Cancer Control (UICC) 2017.
8.
go back to reference Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C, Yamamoto Y, Ohashi Y. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017;20(2):217–25.CrossRefPubMed Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C, Yamamoto Y, Ohashi Y. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017;20(2):217–25.CrossRefPubMed
9.
go back to reference Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017;20(Suppl 1):69–83.CrossRefPubMed Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017;20(Suppl 1):69–83.CrossRefPubMed
10.
go back to reference Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, Yoshida K, Daiko H, Sakuramoto S, Yoshikawa T, et al. Mapping of Lymph Node Metastasis from Esophagogastric Junction Tumors: a prospective Nationwide Multicenter Study. Ann Surg. 2021;274(1):120–7.CrossRefPubMed Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, Yoshida K, Daiko H, Sakuramoto S, Yoshikawa T, et al. Mapping of Lymph Node Metastasis from Esophagogastric Junction Tumors: a prospective Nationwide Multicenter Study. Ann Surg. 2021;274(1):120–7.CrossRefPubMed
11.
go back to reference Rosenberg R, Friederichs J, Schuster T, Gertler R, Maak M, Becker K, Grebner A, Ulm K, Höfler H, Nekarda H, et al. Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period. Ann Surg. 2008;248(6):968–78.CrossRefPubMed Rosenberg R, Friederichs J, Schuster T, Gertler R, Maak M, Becker K, Grebner A, Ulm K, Höfler H, Nekarda H, et al. Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period. Ann Surg. 2008;248(6):968–78.CrossRefPubMed
12.
go back to reference Komatsu S, Ichikawa D, Miyamae M, Kosuga T, Okamoto K, Arita T, Konishi H, Morimura R, Murayama Y, Shiozaki A, et al. Positive lymph node ratio as an Indicator of Prognosis and local Tumor Clearance in N3 gastric Cancer. J Gastrointest Surg. 2016;20(9):1565–71.CrossRefPubMed Komatsu S, Ichikawa D, Miyamae M, Kosuga T, Okamoto K, Arita T, Konishi H, Morimura R, Murayama Y, Shiozaki A, et al. Positive lymph node ratio as an Indicator of Prognosis and local Tumor Clearance in N3 gastric Cancer. J Gastrointest Surg. 2016;20(9):1565–71.CrossRefPubMed
13.
go back to reference Komatsu S, Ichikawa D, Nishimura M, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Otsuji E. Evaluation of prognostic value and stage migration effect using positive lymph node ratio in gastric cancer. Eur J Surg Oncol. 2017;43(1):203–9.CrossRefPubMed Komatsu S, Ichikawa D, Nishimura M, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Otsuji E. Evaluation of prognostic value and stage migration effect using positive lymph node ratio in gastric cancer. Eur J Surg Oncol. 2017;43(1):203–9.CrossRefPubMed
14.
go back to reference Lee CHA, Wilkins S, Oliva K, Staples MP, McMurrick PJ. Role of lymph node yield and lymph node ratio in predicting outcomes in non-metastatic colorectal cancer. BJS Open. 2019;3(1):95–105.CrossRefPubMed Lee CHA, Wilkins S, Oliva K, Staples MP, McMurrick PJ. Role of lymph node yield and lymph node ratio in predicting outcomes in non-metastatic colorectal cancer. BJS Open. 2019;3(1):95–105.CrossRefPubMed
15.
go back to reference Amin MBESGF, Byrd DR, et al. editors. AJCC Cancer Staging Manual. 8th ed. New York, NY, USA: Springer International Publishing; 2017. Amin MBESGF, Byrd DR, et al. editors. AJCC Cancer Staging Manual. 8th ed. New York, NY, USA: Springer International Publishing; 2017.
16.
go back to reference Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021, 24(1):1–21. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021, 24(1):1–21.
17.
go back to reference Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRefPubMed Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRefPubMed
18.
go back to reference Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.CrossRefPubMed Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.CrossRefPubMed
19.
go back to reference Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF. Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol. 2007;14(2):306–16.CrossRefPubMed Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF. Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol. 2007;14(2):306–16.CrossRefPubMed
20.
go back to reference Zhang H, Wang W, Diao D, Cheng Y, Song Y, Zhu K, Dang C. Ratio of metastatic to examined lymph nodes, a helpful staging system and independent prognostic factor of esophagogastric junction cancer. PLoS ONE. 2013;8(8):e73238.CrossRefPubMedPubMedCentral Zhang H, Wang W, Diao D, Cheng Y, Song Y, Zhu K, Dang C. Ratio of metastatic to examined lymph nodes, a helpful staging system and independent prognostic factor of esophagogastric junction cancer. PLoS ONE. 2013;8(8):e73238.CrossRefPubMedPubMedCentral
21.
go back to reference Xu J, Cao J, Wang L, Wang Z, Wang Y, Wu Y, Lv W, Hu J. Prognostic performance of three lymph node staging schemes for patients with siewert type II adenocarcinoma of esophagogastric junction. Sci Rep. 2017;7(1):10123.CrossRefPubMedPubMedCentral Xu J, Cao J, Wang L, Wang Z, Wang Y, Wu Y, Lv W, Hu J. Prognostic performance of three lymph node staging schemes for patients with siewert type II adenocarcinoma of esophagogastric junction. Sci Rep. 2017;7(1):10123.CrossRefPubMedPubMedCentral
22.
go back to reference Zhang Y, Liu D, Zeng, Chen C. Lymph node ratio is an independent prognostic factor for patients with siewert type II adenocarcinoma of Esophagogastric Junction: results from a 10-Year follow-up study. J Gastrointest Cancer. 2021;52(3):983–92.CrossRefPubMed Zhang Y, Liu D, Zeng, Chen C. Lymph node ratio is an independent prognostic factor for patients with siewert type II adenocarcinoma of Esophagogastric Junction: results from a 10-Year follow-up study. J Gastrointest Cancer. 2021;52(3):983–92.CrossRefPubMed
23.
go back to reference Attaallah W, Uprak K, Javadov M, Yegen C. Impact of body mass index on number of lymph nodes retrieved in gastric cancer patients. Hepatogastroenterology. 2014;61(136):2425–7.PubMed Attaallah W, Uprak K, Javadov M, Yegen C. Impact of body mass index on number of lymph nodes retrieved in gastric cancer patients. Hepatogastroenterology. 2014;61(136):2425–7.PubMed
24.
go back to reference Choe EK, Park KJ, Ryoo SB, Moon SH, Oh HK, Han EC, Kwon YH. The impact of visceral adipose tissue amount on the adequacy of lymph node retrieval in colorectal cancer surgery. J Surg Oncol. 2018;117(3):523–8.CrossRefPubMed Choe EK, Park KJ, Ryoo SB, Moon SH, Oh HK, Han EC, Kwon YH. The impact of visceral adipose tissue amount on the adequacy of lymph node retrieval in colorectal cancer surgery. J Surg Oncol. 2018;117(3):523–8.CrossRefPubMed
25.
go back to reference Yang Y, Zheng J, Li Y. Comparison of 4 lymph node staging systems for the prognostic prediction of esophagogastric junction adenocarcinoma with ≤ 15 retrieved lymph nodes. Eur J Surg Oncol 2021. Yang Y, Zheng J, Li Y. Comparison of 4 lymph node staging systems for the prognostic prediction of esophagogastric junction adenocarcinoma with ≤ 15 retrieved lymph nodes. Eur J Surg Oncol 2021.
Metadata
Title
Evaluating prognostic value and stage migration effects using a positive lymph node ratio in adenocarcinoma of the esophagogastric junction
Authors
Hajime Kamiya
Shuhei Komatsu
Keiji Nishibeppu
Takuma Ohashi
Hirotaka Konishi
Atsushi Shiozaki
Takeshi Kubota
Hitoshi Fujiwara
Kazuma Okamoto
Eigo Otsuji
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10689-6

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine